anticoagulants

Quote




Anonymous said:
X was not superior to warfarin in the ITT (all else is statistical smoke and mirrors)

Compliance is always WORSE on a QD drug and ALWAYS worse when you can only take said drug at evening with a meal. NO OTHER DRUGS ARE TAKEN THIS WAY AND SO PEOPLE WILL FORGET!! Your half-life of 5 hours will NOT suffice for 48 hrs as well. Double whammy, sonny boy!!

In the real world, family practice offices get 55% TTR on warfarin. But anticoag clinics which make up the majority of patients get 62% and higher which is way better than yours.

In the real world you want to make sure the comparator is as good as you can get, so as not to bias the results. Learn essentials of clinical trials 101 before you even debate this. Whoever gets the highest utility out of their comparator wins because it means the results are more robust and better approximates the bell-curve.

Monitoring is a 10 buck copay on top of 5 dollar warfarin. So half the monthly price with NO DOUGHNUT Hole sliding.

Indications don't mean shit outside of a cost-constrained institution. Why would a family practice guy care that you use Zarelto after someone cuts on a knee or hip, especially since they ain't doing this themselves.
Click to expand...


Ummmm.....What? Compliance is worse on a QD drug? And by any chance did you know your study was an open label study? I never knew that open label trials are the best way to eliminate bias, I must have missed that in your clinical trials 101 class. God I hope you are the Pradaxa rep in my area.
 












Riva is xarelto.
This person has 5 total scripts in 6 weeks.
Our territory has 8.
Half of them are from speakers, but they're also pradaxa speakers.
even the speakers are promoting xarelto 3rd line.
 




Anonymous said:
Ummmm.....What? Compliance is worse on a QD drug? And by any chance did you know your study was an open label study? I never knew that open label trials are the best way to eliminate bias, I must have missed that in your clinical trials 101 class. God I hope you are the Pradaxa rep in my area.
Click to expand...

Hey sweet-cheeks, the trial wasn't any more open-label than Zarelto's trial. even the FDA note that your trial became "unblinded to the investigators" should a bleed occur. The only part of our study was unblinded was the patient knowing which dose strength of coumadin they got. The management of dual arms of p-dax was BLINDED. Get your facts straight. I really hope you talk about this in my clinics. You guys already have a negative view in docs offices pulling out the BID compliance issue when you know full well it's QD compliance issues. I pray at night that your the other rep. Makes my life easier.

Also, do you tell docs it takes 13 days to get an INR on a patient when transitioning back to warf? That's OK, I'll help you out and do it for you.

Do you tell docs, the crazy GI effects of your (55% more GI bleeds on Zarelto vs uncontrolled warf)? That's OK, I'll help you out and do it for you.

Do you tell docs that the American arm of your trial shows 50% more Major bleed on Zarelto over uncontrolled warf? That's OK, I'll help you out and do it for you.

What about the 20% more non-clinically rel bleeds in the USA arm? That's OK, I'll help you out and do it for you.

What about most of your data-set is derived from, gasp, Eastern Europe????? That's OK, I'll help you out and do it for you.

What about that if you don't take this drug at night with food its "ineffective"? That's OK, I'll help you out and do it for you.
 




Anonymous said:
alert

December 19, 2011 Heartwire
RECOVER II confirms benefit of dabigatran in treatment of VTE

San Diego, CA - Data from the RECOVER II study confirms the safety and efficacy of dabigatran (Pradaxa, Boehringer Ingelheim) when compared with warfarin for the treatment of patients with acute venous thromboembolism (VTE) [1]. The new study included significantly more Asian patients than the 2500-patient RECOVER trial, note investigators, and the rates of recurrent VTE and bleeding were similar in these patients and non-Asian patients.

RECOVER II, presented last week at the American Society of Hematology 2011 Annual Meeting, led by Dr Sam Schulman (McMaster University, Hamilton, ON), was designed to replicate the results of RECOVER, given the low rate of the primary outcome—a composite of recurrent VTE or fatal pulmonary embolism (PE)—in the original trial.
Click to expand...

Lights out Zarelto
 








4 simple words-

Don't

Hold

Your

Breath


-even at 2.5mg bid the ich rate was out of this world, why gork someone out with a stoke to remotely save 1 life in 300. Not worth the risk of malpractice suit and my assets.
 












Worry about "A" not Z, X or P

Apixaban Works in Afib Even With Prior Stroke

By Todd Neale, Senior Staff Writer, MedPage Today
Published: February 03, 2012 Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston.

NEW ORLEANS -- The investigational anticoagulant, apixaban, appears to prevent stroke and systemic embolism in patients with atrial fibrillation regardless of a prior history of stroke or transient ischemic attack, two studies showed.

In a sub-analysis of the ARISTOTLE trial, apixaban held its advantage against warfarin on several outcomes in patients with and without a history of stroke or TIA, according to J. Donald Easton, of the University of California San Francisco.

A prior history of stroke or TIA was not a rate-limiting factor in the demonstration that apixaban was superior to warfarin or aspirin in preventing stroke or systemic emboli in patients with atrial fibrillation.

Note that apixaban also did not lead to more bleeding, including intracranial bleeding, in patients with a history of stroke or TIA.
 




This is crazy. Janssen retail is selling Aciphex and Xarelto............ what a capitalist combo.


PLATO: PPI analysis "raises flag" but should not change practice
JAN 24, 2012 By Lisa Nainggolan

Toronto, ON- A new analysis of the PLATO study has found that use of a proton-pump inhibitor (PPI) was independently associated with a higher rate of cardiovascular events.
 








Anonymous said:
Worry about "A" not Z, X or P

Apixaban Works in Afib Even With Prior Stroke

By Todd Neale, Senior Staff Writer, MedPage Today
Published: February 03, 2012 Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston.

NEW ORLEANS -- The investigational anticoagulant, apixaban, appears to prevent stroke and systemic embolism in patients with atrial fibrillation regardless of a prior history of stroke or transient ischemic attack, two studies showed.

In a sub-analysis of the ARISTOTLE trial, apixaban held its advantage against warfarin on several outcomes in patients with and without a history of stroke or TIA, according to J. Donald Easton, of the University of California San Francisco.

A prior history of stroke or TIA was not a rate-limiting factor in the demonstration that apixaban was superior to warfarin or aspirin in preventing stroke or systemic emboli in patients with atrial fibrillation.

Note that apixaban also did not lead to more bleeding, including intracranial bleeding, in patients with a history of stroke or TIA.
Click to expand...
Hey dumb rep, pdax has already had this same data set for awhile now, apixaban is always a day late and a dollar short.
 








Top Bottom
Back
Quote